Chongqing Porton Fine Chemicals

Chongqing Porton Fine Chemicals

Founded in 2005, Chongqing Porton Fine Chemicals emerged from China's western industrial base in Chongqing to provide outsourced pharmaceutical R&D and production. The firm supplies pharmaceutical intermediates and active pharmaceutical ingredients (APIs) to biopharmaceutical companies globally, with a portfolio concentrated on innovative drugs targeting infectious diseases. Its early anchor was process chemistry for antiviral therapies, a positioning that gave Porton entry into Western biotech supply chains early in the CDMO outsourcing wave. Porton's strategy rests on the CDMO spectrum — from route scouting and process development through to pilot-scale and commercial cGMP manufacturing. The firm covers small-molecule APIs and advanced intermediates, with disclosed capacity for multi-ton production of high-potency compounds. Therapeutic focus areas include antivirals for HIV and hepatitis C, metabolic disease treatments, and oncology agents. Porton supplies Gilead Sciences with a key intermediate for hepatitis C combination therapies, a relationship that put the firm on global allocator watchlists when Sovaldi and Harvoni regimens reshaped antiviral care. The company also holds relationships with European and US emerging biotechs that require rapid scale-up from preclinical chemistry to Phase III supply. Geographically, it operates from its Chongqing headquarters complex and serves clients across North America, Europe, and Japan — export manufacturing accounts for the bulk of revenue. Porton is publicly traded on the Shenzhen Stock Exchange under ticker 300363, with a market capitalization that has fluctuated with the biotech cycle. The firm employs a technical workforce of process chemists, engineers, and quality-assurance personnel spread across multiple Chongqing sites. Adjacent to its API business, Porton has expanded into formulation development and analytical services, mirroring the vertical integration path of larger CDMO peers. Capital investment in recent years has centered on expanding high-containment manufacturing suites for oncology APIs and upgrading quality systems to meet evolving FDA and EMA inspection standards. Structurally, Porton represents a distinct category in Chinese pharmaceutical outsourcing: an independent, publicly listed CDMO whose fortunes are tied to foreign innovative drug pipelines rather than to domestic generic volume. Its Chongqing location gives it cost advantages over coastal operations while challenging it to attract top-tier process development talent. The firm's regulatory history includes multiple FDA inspections and establishment of drug master files with the US regulator, making it a credible supplier in the global small-molecule supply chain.